Also, when we performed a similar analysis on response to immune checkpoint therapies among patients with clear cell renal carcinoma, we did not find significant differences in CD3E-PDCD1 correlation in responders and non-responders [52]. This evidence concerns the gene CD3E and clear cell renal carcinoma.